Close Menu

NEW YORK — Irish diagnostics firm Trinity Biotech reported on Tuesday a 13 percent year-over-year decline in fourth quarter revenues amid a sharp drop in sales of its point-of-care testing products.

The company also noted that it is working on two SARS-CoV-2 tests, including a rapid point-of-care assay that is expected to be fully developed within the next two months.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.